Sort   by:  
 Page size 
TranscriptomicsIdentifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling (Illumina)
Here we profile prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total RNA was isolated from established prostate cancers in 3 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-
ORGANISM(S): Mus musculus 
2015-02-20 | E-GEOD-61379 | biostudies-arrayexpress
TranscriptomicsIdentifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]
Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total DNA was isolated from established prostate cancers in 4 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-, Pten-/- Rosa26-ERG, and 3 cell lines derived from GEM mod...
ORGANISM(S): Mus musculus 
2015-02-20 | E-GEOD-61382 | biostudies-arrayexpress
TranscriptomicsPTEN intact and NULL prostates in intact and castrate mice.
We performed expression profiling of prostates of 3 month wild-type and PTEN NULL mice and assessed the response to 3 days of castration. Seven three month old WT and PbCre x PTEN f/f (PTEN NULL) mice were used. They are in the C57B6 background. Three mice in each group were castrated. Three days af...
ORGANISM(S): Mus musculus 
2011-05-19 | E-GEOD-24691 | biostudies-arrayexpress
TranscriptomicsIdentification of PHLPP1 as a tumor suppressor reveals the role of feedback compensation in PTEN-mutant prostate cancer progression
Hyper-activation of the PI 3-Kinase/ AKT pathway is a driving force of many cancers. Here we identify the AKT-inactivating phosphatase PHLPP1 as a prostate tumor suppressor. We show that Phlpp1-loss causes neoplasia and, upon partial Pten-loss, carcinoma in mouse prostate. This genetic setting initi...
ORGANISM(S): Mus musculus 
2011-08-16 | E-GEOD-30987 | biostudies-arrayexpress
UnknownA prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
Not available
S-EPMC12056793 | biostudies-literature
UnknownPlasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Not available
S-EPMC11869088 | biostudies-literature
UnknownMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861 | biostudies-literature
Sort   by:  
 Page size